Skip to main content
Toggle navigation
Login
Search
Home
Browse by Community
Home
Browse by Community
Browse by Community
Type here to filter the list
Biologics (BIO)
PII-001 - APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT
Favorite
PII-002 - DEVELOPMENT OF A TRANSLATION PK-PD MODEL FOR IN VIVO CAR-T CELL THERAPIES USING CAR MRNA LOADED POLYMERIC NANOPARTICLE VECTOR
Favorite
PII-003 - EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.
Favorite
PII-004 - MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.
Favorite
Biomarkers & Translational Tools (BTT)
LB-006 - ARTERIAL STIFFNESS AND SYSTEMIC VASCULAR CORRELATES OF BRAIN AMYLOIDOSIS AND PRECLINICAL AD
Favorite
PT-015 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Favorite
PT-018 - MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS
Favorite
PT-019 - ESTABLISHING A PARAMOUNT QUANTITATIVE FRAMEWORK LINKING DISEASE PROGRESSION AND CLINICAL OUTCOMES FOR PARKINSONS DISEASE
Favorite
OAI-001 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
PII-005 - A NOVEL ENDOTYPE OF ADULT ASTHMA SUGGESTED BY PLASMA METABOLITE PROFILING OF THE COHORT FOR REALITY AND EVOLUTION OF ADULT ASTHMA IN KOREA (COREA)
Favorite
PII-006 - A SNAPSHOT OF PHARMACODYNAMIC BIOMARKERS BIOANALYSIS IN 16 BLAS APPROVED FOR NEUROLOGY INDICATIONS.
Favorite
PII-007 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
PII-008 - C-PEPTIDE DISEASE PROGRESSION MODEL IN INDIVIDUALS WITH NEW-ONSET TYPE 1 DIABETES
Favorite
PII-009 - DECIPHERING TYPE 1 DIABETES BY INTEGRATING ARTIFICIAL INTELLIGENCE WITH PANCREATIC WHOLE SLIDE IMAGING
Favorite
PII-010 - EVALUATION OF PLASMA BIOMARKERS TO ASSESS THEIR ABILITY TO PREDICT CYP2D6 ACTIVITY IN INDIVIDUALS INCLUDING PATIENTS WITH TYPE 2 DIABETES.
Favorite
PII-011 - FC GAMMA RECEPTORS CONTRIBUTE TO CACHEXIA MEDIATED INCREASES IN MONOCLONAL ANTIBODY CLEARANCE
Favorite
PII-012 - LEVERAGING COPROPORPHYRIN-I AS AN ENDOGENOUS OATP1B BIOMARKER TO DISENTANGLE THE EFFECTS OF CEDIROGANT IN COMPLEX DRUG-DRUG INTERACTIONS.
Favorite
PII-013 - OPTIMIZATION OF PARKINSON'S DISEASE DIGITAL BIOMARKERS THROUGH CLINICAL TRIAL SIMULATIONS.
Favorite
PII-014 - UNRAVELING IL9 SERUM DISTRIBUTION PATTERNS: INSIGHTS FROM THE CYTOCON DATABASE
Favorite
PII-015 - UTILITY OF MIROMICS AND INTEGRATIVE MULTI-OMICS SYSTEMS ANALYSIS FOR IDENTIFICATION OF MIRNAS AS POTENTIAL PHARMACODYNAMIC BIOMARKERS OF IFNβ-1A BIOLOGICS
Favorite
PWII-002 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Favorite
PWII-003 - MINIMAL SAMPLING TO ASSESS MECHANISMS LINKING IMMUNE CHECKPOINT INHIBITOR PHARMACOKINETICS AND OUTCOMES IN CANCER PATIENTS
Favorite
Cell, Gene, Regenerative Medicine & Nucleic Acid (CGRN)
PII-016 - CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Favorite
PII-017 - CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
Favorite
PII-018 - CLINICAL DOSE PREDICTION FOR CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPIES USING A MULTI-SCALE QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) PLATFORM MODEL
Favorite
PII-019 - COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE
Favorite
PII-020 - EVIDENCE FOR INDUCIBLE CMV PROMOTER ACTIVITY IN HUMAN CHONDROCYTES
Favorite
PII-021 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL)
Favorite
PWI-001 - COMPARISON OF METHODS OF FIRST-IN-HUMAN DOSE PREDICTION FOR ADENO-ASSOCIATED VIRUS-MEDIATED GENE THERAPIES IN FABRY DISEASE
Favorite
Drug Utilization & Outcomes (DUO)
CT-005 - PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Favorite
PT-017 - IMPACT OF CYP2D6 INHIBITORS ON PAIN CONTROL BY THE OPIOIDS
Favorite
PII-023 - PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Favorite
Early Career (EC)
PII-024 - STABILITY OF THE GUT MICROBIOME FROM HUMAN FECAL SAMPLES COLLECTED BY CONTACTLESS REGIONAL SHIPPING AND ITS APPLICATION IN CLINICAL TRIALS.
Favorite
Early Development & Drug Safety (EDDS)
LB-022 - MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.
Favorite
PT-027 - INHIBITION OF TACROLIMUS METABOLISM BY CANNABIDIOL AND ITS METABOLITES IN VITRO.
Favorite
PII-025 - ASCENDING DOSE IN VIVO QT STUDIES HAVE THE SENSITIVITY TO DETECT QT INTERVAL CHANGES THAT ARE SUFFICIENT TO SUPPORT A CLINICAL QT WAIVER: ASSESSMENT OF QT/QTC INTERVAL CHANGES USING AN ESCALATING DOSE DESIGN IN TELEMETERED BEAGLE DOGS.
Favorite
PII-026 - COMPARISON OF CHANGES IN PUPIL DIAMETER AND HYPERCAPNIC VENTILATION FOR OXYCODONE AND PSYCHOTROPIC DRUGS ADMINISTERED ALONE OR IN COMBINATION
Favorite
PII-027 - FORMULATION IMPACT OF SSZ ON MTX EXPOSURE: A REPEAT DDI STUDY FOR A MK2 INHIBITOR BMS-986371
Favorite
PII-028 - NO PHOTOTOXICITY OR PHOTOALLERGY EFFECT WITH MRX-5LBT (10%) LIDOCAINE PATCH ADMINISTRATION
Favorite
PII-029 - PHARMACOKINETIC EVALUATION OF GB1211 IN A NOVEL TABLET FORMULATION, ADMINISTERED UNDER FASTED AND FED CONDITIONS, AND COMPARED TO GB1211 CAPSULES, IN HEALTHY VOLUNTEERS
Favorite
PII-030 - PHASE 1 EVALUATION OF THE SAFETY, TOLERABILITY AND PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE ADENOSINE A1R/A3R AGONIST AST-004 AFTER INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS
Favorite
PII-031 - REVIEW OF TRANSLATIONAL CANCER RESEARCH TARGETING ADENOSINE RECEPTOR A2AR.
Favorite
PII-032 - WHAT TO EXPECT FROM A PHENYTOIN DRUG-DRUG INTERACTION STUDY: ADVERSE EVENT PROFILING AND SAFETY ASSESSMENT
Favorite
TIP-002 - DRUG-GENE-NUTRACEUTICAL INTERACTIONS OF CANNABIDIOL AND TACROLIMUS.
Favorite
TIP-003 - EVALUATING THE IMPACT OF XIAO-CHAI-HU-TANG ON PHARMACOKINETIC BEHAVIORS OF IRINOTECAN, RALOXIFENE AND THEIR METABOLITES IN HUMANS: A RUN-IN SAFETY STUDY.
Favorite
Global Health (GH)
PII-033 - EXPANDING THE USE OF REAL-WORLD DATA TO ANSWER CLINICAL PHARMACOLOGY QUESTIONS: DEVELOPMENT OF A USER-FRIENDLY DASHBOARD TO ASSESS PREVALENCE OF ORGAN IMPAIRMENT IN PATIENTS IN THE REAL-WORLD SETTING.
Favorite
PII-034 - THE FEASIBILITY OF PHARMACOKINETIC-GUIDED HYDROXYUREA DOSING FOR CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA: ANALYSIS OF THE ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT) TRIAL.
Favorite
Infectious Diseases (INF)
LB-012 - DEVELOPMENT OF LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF ANTI-NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE DRUGS IN HUMAN PLASMA
Favorite
PII-035 - A BIOEQUIVALENCE AND FOOD EFFECT CLINICAL STUDY OF ZOLIFLODACIN, FIRST-IN-CLASS ORAL ANTIBIOTIC, BEING DEVELOPED FOR THE TREATMENT OF UNCOMPLICATED GONORRHEA
Favorite
PII-036 - EFAVIRENZ AND DOLUTEGRAVIR MAY ALTER SIROLIMUS METABOLISM IN PEOPLE WITH HIV
Favorite
PII-037 - FIH STUDY OF INTRAVENOUS RECCE327: A NOVEL, BROAD SPECTRUM, SYNTHETIC ANTI-INFECTIVE
Favorite
PII-038 - PK/PD OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL IN MACROPHAGES INFECTED WITH M. TUBERCULOSIS.
Favorite
PII-039 - PLERIXAFOR AS PATHOGEN AGNOSTIC PROPHYLAXIS OR ADVUVANT TREATMENT
Favorite
PII-040 - THE IMPACT OF HIV-1 TAT AND MORPHINE ON SPATIAL DISTRIBUTION OF DRUGS IN THE BRAIN.
Favorite
Membrane Transporter (MT)
PII-041 - A CHEMICAL BIOLOGY STRATEGY FOR PREDICTING OATP1B-TYPE TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION (DDI) LIABILITIES
Favorite
PII-042 - DEVELOPMENT OF A NOVEL FLUORESCENCE-BASED APPROACH FOR SOLUTE CARRIER-FOCUSED CRISPR/CAS9 KNOCKOUT SCREENING IN BREAST CANCER CELLS
Favorite
TIP-001 - A CLINICAL STUDY OF NOVEL BCRP AND ESTABLISHED OATP BIOMARKERS FOR PREDICTING DRUG-DRUG INTERACTIONS.
Favorite
Mental Health & Addiction (MHA)
AI-005 - PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Favorite
PT-002 - POST-TRANSCRIPTIONAL GENE REGULATION AND ANTIDEPRESSANT TREATMENT RESPONSE: FUNCTIONAL CHARACTERIZATION OF ELAVL2 RNA-BINDING PROTEIN IN IPSC-DERIVED NEURONS.
Favorite
PT-009 - PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Favorite
PT-012 - THE EFFECT OF BUPRENORPHINE VERSUS METHADONE TREATMENT ON NEUROCOGNITIVE IMPAIRMENT IN PERSONS WITH HIV AND OPIOID USE DISORDER.
Favorite
PII-043 - ANTIDEPRESSANT EXPOSURE IN THE ADOLESCENT BRAIN: FLUOXETINE AND PHARMACOGENETIC INFLUENCES ON BRAIN DISPOSITION
Favorite
PII-044 - KNOWLEDGE, ATTITUDES, AND AWARENESS TOWARD MARIJUANA USE AT HISTORICALLY BLACK UNIVERSITY
Favorite
Oncology (ONC)
CT-011 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Favorite
CT-012 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Favorite
LB-025 - PHARMACOKINETICALLY-GUIDED DOSING OF ORAL SORAFENIB IN PATIENTS WITH PEDIATRIC HEPATOCELLULAR CARCINOMA
Favorite
PT-023 - EFFECT OF STEROID SPARING IMMUNOSUPPRESSIVE AGENTS USED IN THE TREATMENT OF IMMUNE RELATED ADVERSE EVENTS ON TUMOR OUTCOMES IN MELANOMA AND NON-SMALL CELL LUNG CANCER
Favorite
OAI-003 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Favorite
PII-045 - ACETYLATION-DEPENDENT REGULATION OF NUCLEAR PD-L1 IS CRITICAL TO SISTER CHROMATID COHESION IN TRIPLE NEGATIVE BREAST CANCER
Favorite
PII-046 - AN EVALUATION OF THE DRUG INTERACTION POTENTIAL OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS
Favorite
PII-047 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE
Favorite
PII-048 - APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.
Favorite
PII-049 - CLINICAL PHARMACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.
Favorite
PII-050 - CLINICAL PHARMACOLOGY OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Favorite
PII-051 - ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)
Favorite
PII-052 - ETHNIC SENSITIVITY ASSESSMENT OF MOSUNETUZUMAB PHARMACOKINETICS (PK) IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL)
Favorite
PII-053 - EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).
Favorite
PII-054 - EVALUATION OF PHARMACOKINETICS (PK), SERUM CYTOKINES, AND SAFETY FOLLOWING INTRAVENOUS (IV) OR SUBCUTANEOUS (SC) STEP-UP DOSING OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RECURRENT OVARIAN CANCER (OC)
Favorite
PII-056 - IMMUNOGENICITY AND SBMCA CHANGE IN THE COMPARISON OF TALQUETAMAB RECOMMENDED PHASE 2 DOSES
Favorite
PII-057 - INTEGRATED PHARMACOKINETIC (PK)/PHARMACODYNAMIC MODELING OF PK, SAFETY, AND EFFICACY DATA TO SUPPORT DOSE OPTIMIZATION OF BMS-986158, A BROMODOMAIN AND EXTRA-TERMINAL INHIBITOR (BETI), IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF).
Favorite
PII-058 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)
Favorite
PII-059 - MODELING M-PROTEIN DYNAMICS IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING VENETOCLAX: UTILITY OF EARLY M-PROTEIN MONITORING TO PREDICT PROGRESSION FREE SURVIVAL
Favorite
PII-060 - PHARMACOKINETICS (PK) AND SOLUBLE MET (SMET) PHARMACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
Favorite
PII-061 - PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS
Favorite
PII-062 - PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Favorite
PII-063 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Favorite
PII-064 - POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
PII-065 - POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
Favorite
PII-066 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Favorite
PII-067 - POPULATION PHARMACOKINETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
Favorite
PII-068 - REDUCED SYSTEMIC EXPOSURE TO A CAPECITABINE METABOLITE 5'-DFUR IN ABCC4 POLYMORPHISM MAY BE ASSOCIATED WITH INCREASES IN CAMP LEVEL AND SUBSEQUENT UPREGULATION OF THYMIDINE PHOSPHORYLASE
Favorite
PII-069 - THE ANTI-OSTEOCLASTIC EFFECTS AND BONE-AFFINITY PROPERTIES OF GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITOR RAM2061
Favorite
PII-070 - TUCATINIB DOES NOT INCREASE PACLITAXEL PLASMA CONCENTRATIONS IN PATIENTS WITH HER2+ GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Favorite
PII-071 - UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
Favorite
PWII-001 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) TO COMPARE PD-1 AND PD-L1 TREATMENT OUTCOMES IN METASTATIC (M) NON-SMALL-CELL LUNG CANCER (NSCLC)
Favorite
Pharmacogenomics (PGx)
E-001 - INVESTIGATION OF THE RELATIONSHIP BETWEEN LEPR GENOTYPE-LEPTIN-GUT MICROBIOTA COMPOSITION IN HEALTHY NON-OBESE KOREAN ADULTS.
Favorite
CT-009 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
PT-004 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Favorite
PT-005 - INTEGRATED GENOMICS AND TRANSCRIPTOMICS ANALYSES USING HAPMAP CELL LINES REVEAL NOVEL MODULATORS OF CELLULAR RESPONSE TO CYCLOPHOSPHAMIDE.
Favorite
PT-006 - A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.
Favorite
PT-010 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
PT-013 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Favorite
PT-021 - DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.
Favorite
PII-072 - A VALUE PROPOSITION FOR USING PHARMACOGENETIC TESTING IN MENTAL HEALTH CARE
Favorite
PII-073 - ADDRESSING THE RACIAL DISPARITY OF ANGIOTENSIN INHIBITOR ASSOCIATED REDUCTION IN HFREF HOSPITALIZATIONS: DISTINGUISHING BETWEEN RACE AND ANCESTRY
Favorite
PII-074 - BIPOLAR DISORDER GWAS IDENTIFIED A SNP SIGNAL IN THE THSD7A GENE THAT IS ASSOCIATED WITH RESPONSE TO VALPROATE AND LAMOTRIGINE.
Favorite
PII-075 - DNA METHYLTRANSFERASE INHIBITOR SYNERGIZE WITH IMMUNE CHECK POINT INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
Favorite
PII-076 - ESTIMATED PREVALENCE OF ACTIONABLE EXPOSURES TO PHARMACOGENETIC SUPPORTIVE CARE MEDICATIONS AMONG PATIENTS WITH GASTROINTESTINAL CANCERS.
Favorite
PII-077 - EVALUATING THE ACCURACY OF PHARMACOGENOTYPE EXTRACTION FROM SOMATIC WHOLE EXOME SEQUENCING
Favorite
PII-078 - EVALUATION OF G6PD ACTIVITY IN ALL OF US
Favorite
PII-079 - IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES
Favorite
PII-080 - IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
Favorite
PII-081 - MISS SCORES VARY IN ACCORDANCE WITH SLCO1B1 STATUS IN A COHORT OF JIA PATIENTS
Favorite
PII-082 - PERSPECTIVES ABOUT THE DEVELOPMENT AND IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT TOOLS IN RURAL AND UNDERSERVED COMMUNITIES
Favorite
PII-083 - PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.
Favorite
PII-084 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: A GENETIC DETERMINANT OF MYOCARDIAL RECOVERY
Favorite
PII-085 - POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE
Favorite
PII-086 - RACIAL DIFFERENCES IN THE ASSOCIATION BETWEEN UGT1A1*28 AND GENE EXPRESSION OF UGT1A1 AND SEARCHING FOR NOVEL REGULATORY VARIANTS OF UGT1A1.
Favorite
PII-087 - REDUCTION OF NEXT-GENERATION SEQUENCING FILE SIZE FOR EFFICIENT PHARMACOGENOTYPE EXTRACTION.
Favorite
PII-088 - RISK DETERMINANTS FOR DRUG-INDUCED LIVER INJURY WITH COMMON ANTIBIOTICS IN THE ALL OF US RESEARCH PROGRAM
Favorite
PII-089 - STEREOSELECTIVE METABOLISM OF TRIHEXYPHENIDYL: THE PATHWAY TO PRECISION DOSING
Favorite
OAII-001 - EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
Favorite
OAII-002 - ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
Favorite
OAII-004 - CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Favorite
Pharmacometrics & Pharmacokinetics (PMK)
E-003 - UNLOCKING THE DATA MYSTERY: A SIMULATION BASED DECISION GUIDE TO EVALUATE MISSING DATA IN BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES.
Favorite
AI-001 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Favorite
AI-002 - APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Favorite
AI-006 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Favorite
AI-007 - MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE
Favorite
CT-010 - COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS
Favorite
LB-001 - A GENERIC TACROLIMUS CAPSULE SHOWN NOT TO BE BIOEQUIVALENT TO THE BRAND TACROLIMUS CAPSULE IN A POST-APPROVAL PHARMACOKINETIC BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS
Favorite
LB-005 - A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AMX0035 IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Favorite
LB-010 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Favorite
LB-015 - FOOD AND CO-ADMINISTRATION OF ACID REDUCING AGENTS (ARAS) HAVE NO CLINICALLY SIGNIFICANT EFFECT ON THE PHARMACOKINETICS OF ETRUMADENANT - A POPULATION PHARMACOKINETIC (POPPK) AND PHYSIOLOGICALLY-BASED MODELING EXPLORATION.
Favorite
LB-016 - IMPROVED NONCOMPARTMENTAL HALF-LIFE ESTIMATION WITH TOBIT REGRESSION.
Favorite
LB-017 - MACHINE LEARNING MODELING TO PREDICT INFLIXIMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE
Favorite
LB-018 - MODEL BASED META ANALYSIS OF IMATINIB PHARMACOKINETICS: IN ABCB1, ABCG2, AND CYP3A5 GENOTYPES.
Favorite
LB-019 - MODEL-INFORMED DOSE OPTIMIZATION FOR PROPHYLACTIC PIPERACILLIN-TAZOBACTAM IN PERIOPERATIVE PEDIATRIC PATIENTS.
Favorite
LB-020 - MODEL-INFORMED DRUG DEVELOPMENT APPROACH FOR APPROVAL OF INTRAVENOUS FORMULATION OF SECUKINUMAB IN PSORIATIC ARTHRITIS (PSA), ANKYLOSING SPONDYLITIS (AS) AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)
Favorite
LB-021 - MORPHINE-METABOLITE POPULATION PHARMACOKINETIC MODELING IN NEONATES WITH NEONATAL OPIOID WITHDRAWAL SYNDROME FOLLOWING ORAL ADMINISTRATION OF MORPHINE.
Favorite
LB-029 - POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) ANALYSES OF MULTIPLE INTRAVENOUS INFUSIONS OF NX210C PEPTIDE IN HEALTHY ELDERLY VOLUNTEERS (HEVS)
Favorite
LB-030 - POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE TO OPTIMIZE TUBERCULOSIS TREATMENT: AN INTERETHNIC COHORT STUDY OF DIABETES MELLITUS EFFECT ON DRUG EXPOSURE.
Favorite
LB-031 - POPULATION PHARMACOKINETICS OF BORTEZOMIB: MODEL-BASED META-ANALYSIS
Favorite
LB-034 - THE POPULATION PHARMACOKINETICS STUDY OF ANTI-TUMOR B AMONG HEALTHY VOLUNTEER AND ORAL CANCER PATIENTS TO INFORM DOSE DECISION
Favorite
LB-037 - UTILIZING MODEL BASED META-ANALYSIS TO CHARACTERIZE BREAKTHROUGH BLEEDING AND SPOTTING IN WOMEN USING HORMONAL CONTRACEPTIVES
Favorite
PT-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Favorite
PT-007 - APPLICATION OF MACHINE LEARNING COMBINED WITH POPPK AND QSP MODELS FOR ADVERSE EVENTS RISK PREDICTION OF A CD19-TARGETING BISPECIFIC THERAPY
Favorite
PT-008 - PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Favorite
PT-011 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING WITH PAIRED PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF LEVETIRACETAM IN PATIENTS WITH EXTERNAL VENTRICULAR DRAINS.
Favorite
PT-020 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Favorite
PT-028 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Favorite
OAI-004 - ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL
Favorite
PII-090 - A PHARMACOKINETIC AND ENZYME TURNOVER MODEL PREDICTS MAJOR ROLES FOR CYP2B6 GENOTYPES ON THE MAGNITUDE OF EFAVIREZ AUTOINDUCTION OF METABOLISM AND CLEARNCE IN HEALTHY VOLUNTEERS
Favorite
PII-091 - A PHASE 1 OPEN-LABEL, FIXED-SEQUENCE 3-PERIOD STUDY TO EVALUATE PHARMACOKINETIC INTERACTIONS BETWEEN FIMASARTAN AND INDAPAMIDE IN HEALTHY VOLUNTEERS
Favorite
PII-092 - A PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECTS AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099318 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Favorite
PII-093 - A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF A SINGLE DOSE OF DAZODALIBEP IN HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS.
Favorite
PII-094 - A PHASE 1, SINGLE ASCENDING DOSE (SAD) STUDY OF FOOD EFFECT AND DRUG-DRUG INTERACTION (DDI) EFFECTS OF PH-MODIFYING AGENTS ON INCB099280 PHARMACOKINETICS (PK), A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR, IN HEALTHY PARTICIPANTS
Favorite
PII-095 - A POPULATION PHARMACOKINETIC (PK) MODEL OF MILVEXIAN, A SMALL MOLECULE FACTOR XIA INHIBITOR, IN HEALTHY VOLUNTEERS.
Favorite
PII-096 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Favorite
PII-097 - AN INTEGRATED ASSESSMENT OF THE AME PROPERTIES OF SELTOREXANT UTILIZING PRECLINICAL IN VITRO, IN VIVO, AND HUMAN ADME DATA.
Favorite
PII-098 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Favorite
PII-099 - AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE: JOINT LONGITUDINAL-SURVIVAL DISEASE PROGRESSION MODELS.
Favorite
PII-100 - BOSUTINIB MODEL-INFORMED PEDIATRIC DOSE RECOMMENDATIONS FOR LABEL SIMPLIFICATION
Favorite
PII-101 - CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
Favorite
PII-102 - CLINICAL DRUG-DRUG INTERACTION STUDY INTEGRATED WITH PBPK MODELLING PROVIDES INSIGHTS INTO THE INDUCTION POTENTIAL OF MAVACAMTEN ACROSS CYP2C19 PHENOTYPES.
Favorite
PII-103 - CLINICAL PHARMACOLOGY CHARACTERIZATION OF BLINATUMOMAB FROM SUBCUTANEOUS (SC) DOSING IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Favorite
PII-104 - CLINICAL TRIAL SIMULATIONS FOR OPTIMAL SAMPLING TO ASSESS DURABILITY OF PCV IMMUNE RESPONSE IN ADULTS.
Favorite
PII-105 - COMBINED PARENT AND PAYLOAD POPULATION PHARMACOKINETIC MODELING TO SUPPORT DOSE RECOMMENDATION OF THE NOVEL ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE (ADC) SHR-A1921.
Favorite
PII-106 - COMPARATIVE PHARMACOKINETICS AND SAFETY OF DWJ1451 AND CO-ADMINISTRATION OF OLMESARTAN MEDOXOMIL/AMLODIPINE/ROSUVASTATIN AND EZETIMIBE TABLETS IN HEALTHY KOREAN SUBJECTS
Favorite
PII-107 - COMPARATIVE PHARMACOKINETICS/PHARMACODYNAMICS OF FIXED-DOSE COMBINATION OF RABEPRAZOLE/MAGNESIUM OXIDE 10/350MG (DHNP-2001A) TO THE CONVENTIONAL ENTERIC-COATED RABEPRAZOLE 10MG
Favorite
PII-108 - DEVELOPING A PEDIATRIC ORAL SUSPENSION FORMULATION OF ABROCITINIB: A RELATIVE BIOAVAILABILITY AND PALATABILITY ASSESSMENT STUDY IN ADULTS
Favorite
PII-109 - DRUG-DRUG INTERACTION (DDI) STUDY OF THE PROTEOLYSIS TARGETING CHIMERA (PROTAC) ANDROGEN RECEPTOR (AR) DEGRADER BAVDEGALUTAMIDE IN COMBINATION WITH THE P-GLYCOPROTEIN (P-GP) SUBSTRATE FEXOFENADINE IN HEALTHY MALE VOLUNTEERS.
Favorite
PII-110 - DRUG-DRUG INTERACTION EFFECT OF STEADY STATE LAZERTINIB EXPOSURE ON THE SINGLE-DOSE PHARMACOKINETICS OF MIDAZOLAM, ROSUVASTATIN AND METFORMIN.
Favorite
PII-111 - DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF STRONG CYP3A INHIBITION AND P450 INDUCTION ON THE PHARMACOKINETICS OF AFICAMTEN, AND THE EFFECT OF AFICAMTEN ON P-GLYCOPROTEIN, IN HEALTHY PARTICIPANTS.
Favorite
PII-112 - EARLY MEROPENEM PHARMACOKINETICS AND TARGET ATTAINMENT IN CHILDREN WITH SEVERE VS NON-SEVERE SEPSIS
Favorite
PII-114 - EVALUATION OF HIGH-DOSE VUTIGLABRIDIN IN HEALTHY PARTICIPANTS: SAFETY, FOOD EFFECT, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS
Favorite
PII-115 - EVALUATION OF THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON ROSUVASTATIN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.
Favorite
PII-116 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Favorite
PII-117 - EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
Favorite
PII-118 - EXTRAPOLATION APPROACH FOR UPADACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS LEVERAGING PHARMACOKINETICS, EXPOSURE-RESPONSE, AND REAL-WORLD PATIENT DATA.
Favorite
PII-119 - IMPACT OF CRUSHING OR GRINDING ON THE RELATIVE BIOAVAILABILITY OF THE VENETOCLAX TABLETS.
Favorite
PII-120 - IMPACT OF MODERATE OR SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SOTORASIB AND ITS METABOLITES
Favorite
PII-121 - IMPLEMENTATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING IN TRANSLATION AND DOSE SELECTION FOR FIRST-IN-HUMAN PHASE 1/2 CLINICAL STUDY OF NTLA-2002 IN THE TREATMENT OF HEREDITARY ANGIOEDEMA
Favorite
PII-122 - INCREASED DOSE CORRECTED AUC FOLLOWING SLOW SUBCUTANEOUS, INTRAMUSCULAR AND ORAL VERSUS INTRAVENOUS BOLUS HUMAN DRUG DOSING AND ITS POTENTIAL FOR INCREASED DOSE CORRECTED PHARMACODYNAMIC EFFECTS.
Favorite
PII-123 - METABOLIC PROFILING OF ECOPIPAM
Favorite
PII-124 - METABOLISM AND DISPOSITION OF [14C]-ONC201 (DORDAVIPRONE) IN HEALTHY ADULT PARTICIPANTS
Favorite
PII-125 - MICRODOSING APPROACH TO EVALUATE WHETHER ECOPIPAM AFFECTS DRUG METABOLISM AND TRANSPORT OF CONCOMITANT MEDICATIONS
Favorite
PII-126 - MODEL-BASED META-ANALYSIS (MBMA) OF OBJECTIVE RESPONSE RATE (ORR) AND GRADE 3+ TREATMENT-RELATED ADVERSE EVENTS (G3TRAE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC).
Favorite
PII-127 - MODELING AND SIMULATION TO EXPLORE MECHANISMS OF PHARMACOKINETIC DRUG-DRUG INTERACTIONS OF ABEMACICLIB AND OLAPARIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Favorite
PII-128 - NOVEL NONLINEAR POPULATION PHARMACOKINETIC MODEL OF IMETELSTAT, A FIRST-IN-CLASS OLIGONUCLEOTIDE TELOMERASE INHIBITOR
Favorite
PII-129 - ONDANSETRON FOR THE TREATMENT OF NEONATAL OPIOID WITHDRAWAL SYNDROME.
Favorite
PII-131 - PHARMACOKINETIC PARAMETER ESTIMATION OF GENTAMICIN IN AN OBESE HEMODIALYSIS PATIENT: A CASE REPORT
Favorite
PII-132 - PHARMACOKINETICS AND SAFETY OF MAVACAMTEN IN HEALTHY CHINESE SUBJECTS WITH DIFFERENT CYP2C19 PHENOTYPES
Favorite
PII-133 - PHARMACOKINETICS OF EDARAVONE - COMPARISON OF EXPOSURE BETWEEN JAPANESE AND NON-JAPANESE BY POPULATION PHARMACOKINETIC ANALYSIS.
Favorite
PII-134 - PHARMACOKINETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATION
Favorite
PII-135 - PHARMACOKINETICS OF MONOCLONAL ANTIBODIES THROUGHOUT PREGNANCY: A SYSTEMATIC LITERATURE REVIEW
Favorite
PII-136 - PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
Favorite
PII-137 - PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ABBV-552 IN HEALTHY ADULT JAPANESE AND HAN CHINESE SUBJECTS
Favorite
PII-139 - PHARMACOMETRICS-BASED APPROACH TO FIRST-IN-HUMAN INTRAVENOUS DOSE DETERMINATION FOR SRP-6004 IN PATIENTS WITH LIMB GIRDLE MUSCULAR DYSTROPHY 2B
Favorite
PII-140 - PHARMCOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS OF INTRANASALLY ADMINISTERED AND INTRAMUSCULARLY INJECTED EPINEPHRINE
Favorite
PII-141 - PILOT FEASIBILITY STUDY OF AN ORAL CYP3A4/2C19 PROBE COCKTAIL TO PREDICT BORTEZOMIB CLEARANCE IN MULTIPLE MYELOMA PATIENTS
Favorite
PII-142 - POPULATION EXPOSURE–RESPONSE ANALYSIS SUPPORTS EFFICACY OUTCOMES OF GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA.
Favorite
PII-143 - POPULATION PHARMACOKINETIC (PK) MODEL OF AB521, A SMALL MOLECULE INHIBITOR OF HIF-2α, IN HEALTHY PARTICIPANTS.
Favorite
PII-144 - POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NGM707, AN ILT2/ILT4 DUAL ANTAGONIST ANTIBODY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Favorite
PII-145 - POPULATION PHARMACOKINETIC MODELING OF ALNUCTAMAB, A BCMA-BINDING T CELL ENGAGER, TO CHARACTERIZE THE BIOAVAILABILITY AND PHARMACOKINETICS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Favorite
PII-146 - POPULATION PHARMACOKINETIC MODELING OF CAMRELIZUMAB IN PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA.
Favorite
PII-147 - POPULATION PHARMACOKINETIC MODELING OF NGM438 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Favorite
PII-148 - POPULATION PHARMACOKINETIC MODELING OF RIVOCERANIB IN HEALTHY SUBJECTS AND PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
Favorite
PII-149 - POPULATION PHARMACOKINETICS AND TUMOR GROWTH INHIBITION MODELING OF AN ANTI-CLAUDIN 18.2 ADC TO SUPPORT DRUG DEVELOPMENT DECISION-MAKING
Favorite
PII-150 - POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND FLORFENICOL IN THE GIANT DANIO (DEVARIO AEQUIPINNATUS) FOLLOWING ORAL AND BATH ADMINISTRATION
Favorite
PII-151 - POPULATION PHARMACOKINETICS OF REZVILUTAMIDE (SHR3680) WITH TIME-VARYING AND SATURABLE RELATIVE BIOAVAILABLITY IN PROSTATE CANCER PATIENTS
Favorite
PII-152 - PREDICT: A MACHINE LEARNING ALGORITHM FOR PREDICTING PHARMACOKINETIC PROFILES
Favorite
PII-153 - PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT
Favorite
PII-154 - PREDICTIVE MODELING OF TACROLIMUS DOSE REQUIREMENTS AND TRANSPLANTATION OUTCOME IN LUNG TRANSPLANT RECIPIENTS ON SYSTEMIC AZOLE ANTIFUNGALS
Favorite
PII-155 - SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE INTRAVENOUS ADMINISTRATIONS OF LENZILUMAB IN HEALTHY KOREAN SUBJECTS
Favorite
PII-156 - STRAIN- AND ROUTE-DEPENDENT PLASMA PHARMACOKINETICS AND BRAIN PENETRATION OF PACLITAXEL.
Favorite
PII-157 - THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, IN HEALTHY ADULT PARTICIPANTS.
Favorite
PII-158 - THE EFFECT OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER, ON DABIGATRAN PHARMACOKINETICS (PK) IN HEALTHY ADULT PARTICIPANTS.
Favorite
PII-159 - THE NEED FOR EQUITABLE REPRESENTATION IN PHARMACOKINETIC STUDIES TO ENHANCE OPTIMAL DOSING STRATEGIES TO TREAT POVERTY-RELATED DISEASES IN MALNOURISHED CHILDREN.
Favorite
PWI-002 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Favorite
PWI-003 - USE OF QUANTITATIVE MAGNETIC RESONANCE IMAGING BIOMARKERS IN CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY: MULTIVARIATE DISEASE PROGRESSION MODELS BRIDGING TIMED MOTOR FUNCTION TESTS AND FAT FRACTION
Favorite
TIP-005 - POPULATION PHARMACOKINETICS OF LEVOFLOXACIN IN KOREAN AND INDONESIAN TUBERCULOSIS PATIENTS: THE INFLUENCE OF RENAL FUNCTION AND DIABETES MELLITUS ON CLEARANCE.
Favorite
OAII-003 - A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
Favorite
PWII-005 - PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Favorite
Physiological Based Pharmacokinetic Modeling and Simulation (PBPK)
CT-001 - AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Favorite
CT-006 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Favorite
CT-007 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Favorite
LB-002 - A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC (MPBPK) MODEL TO CHARACTERIZE PSA07 BACTERIOPHAGE (PHAGE) PHARMACOKINETICS (PK) FOLLOWING INTRAVENOUS (IV) ADMINISTRATION IN MICE FOR TREATMENT OF P. AERUGINOSA (PSA) INFECTIONS
Favorite
LB-003 - A NOVEL MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC (PBPK-PD) MODEL TO ASSESS DRUG-DRUG INTERACTION (DDI) RISKS FOR ACID REDUCING AGENTS (ARA).
Favorite
LB-004 - A NOVEL PHYSIOLOGICALLY BASED OCULAR PHARMACOKINETIC MODEL INCORPORATING ACCURATE DYNAMICS OF THE ANTERIOR EYE
Favorite
LB-007 - ASSESSING POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING Δ-9-TETRAHYDROCANNABINOL AND CANNABIDIOL IN HEALTHY ADULTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS
Favorite
LB-011 - DEVELOPMENT AND VERIFICATION OF MECHANISTIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR ENZALUTAMIDE AND ITS N-DESMETHYL METABOLITE M2 AS INDUCERS OF CYP3A4
Favorite
LB-026 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR THE PREDICTION OF BCRP-MEDIATED DRUG INTERACTIONS USING R STATISTICAL SOFTWARE
Favorite
LB-027 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO PREDICT HUMAN DOSE OF MITHRAMYCIN ANALOGUE FOR THE TREATMENT OF EWING SARCOMA
Favorite
LB-028 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC DOSING OF OLVEREMBATINIB IN CHILDREN WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Favorite
LB-032 - PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES
Favorite
LB-035 - TOWARDS MORE ROBUST EVALUATION OF THE PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS: USING CONFIDENCE INTERVALS TO SUPPORT USE OF MODEL-INFORMED DOSING IN CLINICAL CARE
Favorite
PT-001 - UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY
Favorite
PT-014 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Favorite
PT-025 - DEVELOPMENT AND VERIFICATION OF A NIFEDIPINE CONTROLLED RELEASE PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL IN PREGNANCY
Favorite
PT-026 - CAN MODEL BASED APPROACHES ACCURATELY IDENTIFY BIO(IN)EQUIVALENCE OF TOPICAL CLOTRIMAZOLE PRODUCTS?
Favorite
OAI-002 - UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY
Favorite
PII-160 - AGE-APPROPRIATE DOSING FOR DEXAMETHASONE TO PREVENT POST-EXTUBATION STRIDOR: A PEDIATRIC PBPK MODELING APPROACH
Favorite
PII-161 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Favorite
PII-162 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Favorite
PII-163 - APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO SUPPORT BIOEQUIVALENCE EVALUATION OF MESALAMINE DELAYED RELEASE TABLETS
Favorite
PII-164 - ASSESSING CYTOCHROME P450 DRUG INTERACTION RISK FOR ONC201 USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Favorite
PII-165 - AUTOMATED QUALIFICATION FRAMEWORK FOR PHYSIOLOGICALLY-BASED QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING
Favorite
PII-166 - DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR BALOVAPTAN AND ITS MAJOR METABOLITE TO EVALUATE THEIR CYP3A4-MEDIATED VICTIM DRUG-DRUG INTERACTION (DDI) LIABILITY
Favorite
PII-167 - DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR VENLAFAXINE AND O-DESMETHYLVENLAFAXINE: ASSESSING THE IMPACT OF CYP2D6, CYP2C9 AND CYP2C19 GENETIC POLYMORPHISMS
Favorite
PII-168 - DEVELOPMENT OF GRAPHICAL INTERFACE IN R SHINY FOR PBPK MODEL-BASED PREDICTION AND SIMULATION OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Favorite
PII-169 - EVALUATION OF THE POTENTIAL IMPACT ON PHAMACOKINETICS OF VARIOUS CYTOCHROME P450 SUBSTRATES OF INCREASING IL-6 LEVELS FOLLOWING ADMINISTRATION OF THE T-CELL BISPECIFIC ENGAGER GLOFITAMAB
Favorite
PII-170 - EXPOSURE OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN LACTATING MOTHERS AND THEIR INFANTS: INSIGHTS FROM A PBPK MODEL
Favorite
PII-171 - IDENTIFY BIOPREDICTIVE DISSOLUTION FOR PREDICTING IN VIVO PERFORMANCE OF A BCS II DRUG PRODUCT UNDER FED CONDITION
Favorite
PII-172 - IN SILICO PREDICTION OF ION CHANNEL EFFECTS OF METHADONE LEADING TO QT INTERVAL PROLONGATION.
Favorite
PII-173 - LEVERAGING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING AND CLINICAL DATA TO PREDICT DRUG-DRUG INTERACTIONS (DDI) OF AVAPRITINIB AND GUIDE DOSE ADJUSTMENTS.
Favorite
PII-174 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE IMPACT OF GENETIC VARIABILITY IN PATIENTS RECEIVING DEXMEDETOMIDINE.
Favorite
PII-175 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY.
Favorite
PII-176 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
Favorite
PII-177 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE GASTRIC ACID MODIFIER EFFECT ON RIMEGEPANT EXPOSURE
Favorite
PII-178 - PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
Favorite
Precision Dosing (PD)
E-002 - MODEL-INFORMED PRECISION DOSING GUIDANCE OF ETHOSUXIMIDE DEVELOPED FROM A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CHIILDHOOD ABSENCE EPILEPSY.
Favorite
Rare Diseases (RD)
PT-024 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Favorite
PII-179 - A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES.
Favorite
PII-180 - CLINICAL PHARMACOLOGY CONSIDERATIONS FOR FIRST-IN-HUMAN CLINICAL TRIALS FOR ENZYME REPLACEMENT THERAPY
Favorite
PII-181 - FLUOROQUINOLONES ATTRIBUTE AORTIC DISEASES THROUGH ENDOTHELIAL DYSFUNCTION.
Favorite
PII-182 - POPULATION PHARMACOKINETICS (PK) AND PK/PHARMACODYNAMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY
Favorite
PII-183 - POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07265803 AND ITS METABOLITE IN PATIENTS WITH LAMIN A/C RELATED DILATED CARDIOMYOPATHY.
Favorite
PII-184 - TOWARDS ASSISTING POTENTIAL PREVENTION CLINICAL TRIALS OF BONE-PROTECTIVE THERAPIES FOR DUCHENNE MUSCULAR DYSTROPHY USING DEEP SEGMENTED IMAGING BIOMARKER
Favorite
PWI-004 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Favorite
Regulatory Science (RS)
PII-185 - A QUANTITATIVE MODELING APPROACH TO PREDICT AVAILABILITY OF GENERIC ORPHAN DRUG PRODUCTS.
Favorite
PII-186 - A SURVEY ON RECOMMENDATION OF FOOD CONDITIONS IN BIOEQUIVALENCE STUDIES WITH PHARMACOKINETIC ENDPOINTS FOR GENERIC ORAL ANTINEOPLASTIC DRUG DEVELOPMENT.
Favorite
PII-187 - ASSESSMENT OF MALE INFERTILITY RISKS TO SUPPORT PRODUCT-SPECIFIC GUIDANCE DEVELOPMENT FOR GENERIC ORAL PRODUCTS.
Favorite
PII-188 - DEEP DIVE INTO GENERIC DRUG APPLICATIONS TO SEEK DATA-DRIVEN HARMONIZATION OF BIOEQUIVALENCE CRITERIA FOR NARROW THERAPEUTIC INDEX DRUGS.
Favorite
PII-189 - EVALUATION OF CARDIOVASCULAR TOXICITY PROFILE OF ALK INHIBITORS USING ADVERSE EVENT REPORTING DATABASE
Favorite
PII-190 - GLOBAL HARMONIZATION OF IMMEDIATE-RELEASE SOLID ORAL DRUG PRODUCT BIOEQUIVALENCE RECOMMENDATIONS AND THE IMPACT ON GENERIC DRUG DEVELOPMENT.
Favorite
PII-191 - PEDIATRIC CLINICAL TRIAL DESIGNS FOR TESTOSTERONE REPLACEMENT THERAPY.
Favorite
PII-192 - SAFETY CONSIDERATIONS OF SUBJECT POPULATION SELECTION IN BIOEQUIVALENCE STUDIES FOR GENERIC DRUG DEVELOPMENT.
Favorite
PII-193 - THE CONTENTS OF IMMUNOGENICITY ASSESSMENT DURING THE REVIEW PROCESS OF NEW DRUG APPLICATION IN JAPAN
Favorite
Special Populations (SPO)
AI-008 - PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Favorite
CT-002 - EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.
Favorite
CT-003 - PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Favorite
CT-004 - PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Favorite
CT-008 - EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.
Favorite
LB-008 - BRILAROXAZINE EFFICACY AND SAFETY IN THE PHASE 3 RECOVER TRIAL IN ACUTE SCHIZOPHRENIA
Favorite
LB-013 - EVALUATION OF SINGLE DOSE AND STEADY STATE PHARMACOKINETICS AND SAFETY OF AMX0035 IN CAUCASIAN AND JAPANESE HEALTHY MALE AND FEMALE PARTICIPANTS.
Favorite
LB-024 - PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Favorite
PII-194 - A PHASE 1 STUDY COMPARING PHARMACOKINETICS OF RIMEGEPANT 25 MG ORALLY DISINTEGRATING TABLET (ODT) PEDIATRIC FORMULATION WITH RIMEGEPANT 75 MG ODT ADULT FORMULATION, WHEN ADMINISTERED AT A SINGLE DOSE OF 75 MG UNDER FASTING CONDITIONS
Favorite
PII-195 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.
Favorite
PII-196 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.
Favorite
PII-197 - CLINICAL EFFECTS OF MEDICAL CANNABIS FOR POST-TRAUMATIC STRESS DISORDER (PTSD) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS - A RETROSPECTIVE COHORT STUDY BASED ON MINNESOTA'S MEDICAL CANNABIS REGISTRY.
Favorite
PII-198 - CLINICAL PHARMACOLOGY CONSIDERATIONS IN EXTRAPOLATION OF EFFICACY AND SAFETY FROM ADULTS TO PEDIATRICS - LESSONS LEARNED FROM PEDIATRIC PROGRAMS OF DIRECT ORAL ANTICOAGULANTS.
Favorite
PII-199 - DESIGN AND MECHANICS OF FIVE MAJOR HUMAN MILK DRUG RESEARCH BIOBANKS: TIME TO CROSS BORDERS AND BARRIERS
Favorite
PII-200 - EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.
Favorite
PII-201 - EFFICACY AND SAFETY OF METFORMIN IN TYPE 2 DIABETIC PATIENTS WITH MILD HEPATIC IMPAIRMENTS: A RETROSPECTIVE COHORT STUDY USING PROPENSITY SCORE MATCHING METHOD.
Favorite
PII-202 - HIGHER CLEARANCE WHILE ON HIGH-DOSE CONTINUOUS DIALYSIS IS ASSOCIATED WITH DECREASED TARGET ATTAINMENT OF PIPERACILLIN IN A PATIENT POST-KIDNEY TRANSPLANT FOR PRIMARY HYPEROXALURIA.
Favorite
PII-203 - KLEBSIELLA PNEUMONIAE CONTRIBUTES TO REDUCE THIOPURINES CYTOTOXICITY IN VITRO: POSSIBLE IMPLICATIONS OF BACTERIAL METABOLISM
Favorite
PII-204 - NEUROLOGIC CONCERNS IN CRITICALLY ILL CHILDREN RECEIVING CEFEPIME
Favorite
PII-205 - PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Favorite
PII-206 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY.
Favorite
PII-207 - PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Favorite
PII-208 - UTILIZING STATISTICAL OR POPULATION PHARMACOKINETIC BASED MATCHING FOR VIRTUAL CONTROL GROUPS IN RENAL AND HEPATIC IMPAIRMENT STUDIES
Favorite
TIP-004 - CHARACTERIZATION OF LABETALOL IN PREGNANCY (THE CLIP STUDY).
Favorite
Student & Trainee (ST)
LB-009 - CANNABIDIOL INCREASES EXPOSURE OF TACROLIMUS IN HEALTHY VOLUNTEERS.
Favorite
LB-014 - EXTRAPOLATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTION BETWEEN REMDESIVIR AND CLOFAZIMINE FROM IN VITRO TO IN VIVO: A STATIC APPROACH
Favorite
PII-209 - MEDICAL SUPPLY TRANSPORT TO EVACUATION SHELTERS BY DRONE: PROPOSAL OF OITA MODEL USING RENDEZVOUS POINTS OF AIR AMBULANCE.
Favorite
Systems Pharmacology (SP)
LB-023 - PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL
Favorite
LB-036 - UNDERSTANDING RELAXIN MECHANISMS OF ACTION THROUGH CARDIORENAL SYSTEMS PHARMACOLOGY MODELING
Favorite
PT-016 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Favorite
PT-022 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF PYRROLOBENZODIAZEPINE-BASED ANTIBODY-DRUG CONJUGATES
Favorite
PII-210 - A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.
Favorite
PII-211 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PRECLINICAL TO CLINICAL TRANSLATION OF ANTIBODY-DRUG CONJUGATE (ADC) EFFICACY AND THROMBOCYTOPENIA.
Favorite
PII-212 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS
Favorite
PII-214 - DEVELOPMENT OF A MECHANISTIC CK-PD MODEL TO QUANTITATIVELY CHARACTERIZE A CD19 DIRECTED CAR-T CELL THERAPY PRODUCT DEVELOPED USING RAPID MANUFACTURING
Favorite
PII-215 - EVALUATING THE EFFICACY OF COMBINATION OF CHECKPOINT INHIBITORS AND CHEMOTHERAPY IN LUNG CANCER USING A MECHANISTIC MODEL
Favorite
PII-218 - QSP MODEL OF RHEUMATOID ARTHRITIS, CAPTURING RANGE OF RESPONSES TO METHOTREXATE, ADALIMUMAB AND TOCILIZUMAB THERAPIES
Favorite
PII-219 - QUANTITATIVE CHARACTERIZATION OF ENHANCED TISSUE DISTRIBUTION AND INNATE KILLING POTENTIAL OF UN-ENGINEERED GAMMA DELTA Ɣδ T CELLS USING A MECHANISTIC MODEL
Favorite
PII-220 - RESPONSE TO LYMPHOCYTE DEPLETING AND LYMPHOCYTE MODULATING THERAPIES IN DIFFERENT POPULATIONS OF PATIENTS WITH MULTIPLE SCLEROSIS INVESTIGATED BY QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL
Favorite
PII-221 - TETRAVALENCY IMPACT ON BISPECIFIC ANTIBODY-ACHIEVED RECEPTOR OCCUPANCY AND TARGET DOWNREGULATION: ESTIMATION BY TRANSLATIONAL PK/RO MODEL OF CTX8371 ANTIBODY
Favorite
PII-222 - VALIDATION OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR CHRONIC HEPATITIS B.
Favorite
PWII-004 - DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL TO EVALUATE THE THERAPEUTIC POTENTIAL OF ANTI-CD19 CAR-T IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Favorite
Translational Informatics (TI)
AI-003 - BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.
Favorite
AI-004 - UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA
Favorite
PII-223 - BRAIN MEASUREMENTS, PERIPHERAL BIOMARKERS, OR BOTH? IMPROVED PREDICTIONS OF RESPONSE TO SERTRALINE THROUGH MULTI-MODAL DATA INTEGRATION.
Favorite
PII-224 - PREDICTORS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) IN A HYPERTENSION (HTN) POPULATION WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Favorite
PII-225 - UNLOCKING HIDDEN DRUG-REPURPOSING OPPORTUNITIES: NLP-POWERED TOPIC MODELING OF UNSTRUCTURED CURE-ID DATA
Favorite
